PCRX - Pacira BioSciences, Inc.
IEX Last Trade
19.575
-0.125 -0.639%
Share volume: 6,255
Last Updated: Fri 27 Dec 2024 05:29:25 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.45%
PREVIOUS CLOSE
CHG
CHG%
$19.70
-0.13
-0.63%
Fundamental analysis
33%
Profitability
28%
Dept financing
32%
Liquidity
75%
Performance
26%
Performance
5 Days
1.41%
1 Month
16.03%
3 Months
35.87%
6 Months
-29.48%
1 Year
-42.09%
2 Year
-50.92%
Key data
Stock price
$19.58
DAY RANGE
$19.50 - $19.97
52 WEEK RANGE
$12.75 - $35.95
52 WEEK CHANGE
-$42.02
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: David M. Stack
Region: US
Website: pacira.com
Employees: 720
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: pacira.com
Employees: 720
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectionable suspension. iovera system produces controlled doses of cold temperature only to targeted nerves.
Recent news